Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K
Second Department of Internal Medicine, School of Medicine, Kobe University.
Jpn J Cancer Res. 1999 Dec;90(12):1380-6. doi: 10.1111/j.1349-7006.1999.tb00723.x.
The interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. The basal-to-apical transport of [14C]docetaxel in LLC-GA5-COL150 cells significantly exceeded that in LLC-PK1 cells, but the apical-to-basal transport was decreased in LLC-GA5-COL150 cells. The intracellular accumulation after its basal or apical application to LLC-GA5-COL150 cells was 4- to 20-fold lower than that of LLC-PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal-to-apical transport and increased the apical-to-basal transport of [14C]docetaxel in LLC-GA5-COL150 cells, but verapamil affected only apical-to-basal transport. The intracellular accumulation after basal or apical application to LLC-GA5-COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp.
使用猪肾上皮LLC-PK1和LLC-GA5-COL150细胞研究了多西他赛(“泰索帝”)与P-糖蛋白(P-gp)的相互作用,通过将人MDR1 cDNA转染到LLC-PK1细胞中,在顶端质膜上选择性过表达人P-gp。LLC-GA5-COL150细胞中[14C]多西他赛从基底到顶端的转运显著超过LLC-PK1细胞,但LLC-GA5-COL150细胞中从顶端到基底的转运减少。将其从基底或顶端应用于LLC-GA5-COL150细胞后,细胞内积累比LLC-PK1细胞低4至20倍。多药耐药(MDR)调节剂,即环孢素A和SDZ PSC 833,抑制了LLC-GA5-COL150细胞中[14C]多西他赛从基底到顶端的转运,并增加了从顶端到基底的转运,但维拉帕米仅影响从顶端到基底的转运。这三种MDR调节剂也增加了将其从基底或顶端应用于LLC-GA5-COL细胞后细胞内的积累。这些观察结果表明多西他赛是人类P-gp的底物,提示多西他赛与药物的相互作用是通过P-gp发生的。在LLC-PK1细胞中也发现了MDR调节剂以及柔红霉素和长春碱对[14C]多西他赛转运的抑制作用,LLC-PK1细胞内源性表达较低水平的P-gp,且显示相似抑制水平的浓度低于LLC-GA5-COL150细胞的情况。这些观察结果表明有必要考虑多西他赛通过P-gp的药代动力学和药效学相互作用。